＜Editors' Choice＞ Pulmonary Hypertension: Diagnosis, Management, and Treatment

Overview

Journal Nagoya J Med Sci

Specialty General Medicine

Date 2019 Apr 10

PMID 30962652

Citations 14

Authors

Takahisa Kondo

Naoki Okumura

Shiro Adachi

Toyoaki Murohara

Affiliations

Soon will be listed here.

Abstract

Pulmonary hypertension (PH) is a hemodynamic state that is characterized by a resting mean pulmonary artery pressure ≧ 25 mmHg. The common forms of PH are pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), PH caused by left-heart disease, and PH due to lung disease. Previously regarded as untreatable, the treatment of PAH has dramatically advanced since the introduction of the drug epoprostenol in 1999, with three-year survival rates improving from 30%-40% to over 85%. Drugs available for the specific treatment of PAH include endothelin-receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogs, and prostacyclin-receptor agonists. In the past decade, management and treatment of CTEPH have also improved. While pulmonary endarterectomy used to be the only option for the treatment of CTEPH, newer treatments include a soluble guanylate cyclase stimulator, which has proven to be an efficacious targeted therapy. Other cases benefit from balloon pulmonary angioplasty.

Citing Articles

Mean pulmonary artery pressure prediction with explainable multi-view cardiovascular magnetic resonance cine series deep learning model.

Cheng L, Sun X, Elliot C, Condliffe R, Kiely D, Alabed S J Cardiovasc Magn Reson. 2024; 27(1):101133.

PMID: 39645082 PMC: 11782807. DOI: 10.1016/j.jocmr.2024.101133.

β-catenin mediates monocrotaline-induced pulmonary hypertension via glycolysis in rats.

Meng H, Deng Y, Liao J, Wu D, Li L, Chen X BMC Cardiovasc Disord. 2024; 24(1):381.

PMID: 39044140 PMC: 11264393. DOI: 10.1186/s12872-024-04000-z.

Under pressure: symptomatic pulmonary hypertension is a predictor of poor outcome following hip fracture.

Ganta A, Merrell L, Esper G, Gibbons K, Egol K, Konda S Eur J Orthop Surg Traumatol. 2024; 34(6):3145-3154.

PMID: 38987403 DOI: 10.1007/s00590-024-04028-z.

Unraveling the Complex Relationship-Atrial Fibrillation and Pulmonary Hypertension.

Aggarwal K, Valleru P, Anamika F, Aggarwal P, Gupta I, Gupta V Curr Cardiol Rep. 2024; 26(9):885-891.

PMID: 38985227 DOI: 10.1007/s11886-024-02089-4.

Clinical usefulness of endothelial progenitor cells in predicting the efficacy of riociguat in chronic thromboembolic pulmonary hypertension.

Imai R, Adachi S, Yoshida M, Shimokata S, Nakano Y, Okumura N Nagoya J Med Sci. 2024; 86(2):292-303.

PMID: 38962405 PMC: 11219221. DOI: 10.18999/nagjms.86.2.292.

References

Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T . Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J. 2011; 76(2):485-8. DOI: 10.1253/circj.cj-11-1217. View

Galie N, Kim N . Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006; 3(7):571-6. DOI: 10.1513/pats.200605-113LR. View

Ghofrani H, DArmini A, Grimminger F, Hoeper M, Jansa P, Kim N . Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369(4):319-29. DOI: 10.1056/NEJMoa1209657. View

Kovacs G, Berghold A, Scheidl S, Olschewski H . Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009; 34(4):888-94. DOI: 10.1183/09031936.00145608. View

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173(9):1023-30. DOI: 10.1164/rccm.200510-1668OC. View

Saji T, Myoishi M, Sugimura K, Tahara N, Takeda Y, Fukuda K . Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension　- Insights From the IBUKI and AIR Studies. Circ J. 2016; 80(4):835-42. DOI: 10.1253/circj.CJ-16-0097. View

Humbert M . Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. Eur Respir Rev. 2010; 19(115):59-63. PMC: 9491634. DOI: 10.1183/09059180.00007309. View

Kim N, Lang I . Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2012; 21(123):27-31. PMC: 9487479. DOI: 10.1183/09059180.00009111. View

Tudorache I, Sommer W, Kuhn C, Wiesner O, Hadem J, Fuhner T . Lung transplantation for severe pulmonary hypertension--awake extracorporeal membrane oxygenation for postoperative left ventricular remodelling. Transplantation. 2014; 99(2):451-8. DOI: 10.1097/TP.0000000000000348. View

10.

Newman J, Wheeler L, Lane K, Loyd E, Gaddipati R, Phillips 3rd J . Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 2001; 345(5):319-24. DOI: 10.1056/NEJM200108023450502. View

11.

Pulido T, Adzerikho I, Channick R, Delcroix M, Galie N, Ghofrani H . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369(9):809-18. DOI: 10.1056/NEJMoa1213917. View

12.

Farber H, Miller D, Poms A, Badesch D, Frost A, Muros-Le Rouzic E . Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015; 148(4):1043-54. DOI: 10.1378/chest.15-0300. View

13.

Soubrier F, Chung W, Machado R, Grunig E, Aldred M, Geraci M . Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D13-21. DOI: 10.1016/j.jacc.2013.10.035. View

14.

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V . Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122(2):156-63. DOI: 10.1161/CIRCULATIONAHA.109.911818. View

15.

Hashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, Masaki T . Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2015; 112(20):E2677-86. PMC: 4443312. DOI: 10.1073/pnas.1424774112. View

16.

Riedel M, Stanek V, Widimsky J, PREROVSKY I . Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982; 81(2):151-8. DOI: 10.1378/chest.81.2.151. View

17.

Dalla Vecchia L, Bussotti M . Exercise training in pulmonary arterial hypertension. J Thorac Dis. 2018; 10(1):508-521. PMC: 5863136. DOI: 10.21037/jtd.2018.01.90. View

18.

Manes A, Palazzini M, Dardi F, DAdamo A, Rinaldi A, Galie N . [Female gender and pulmonary arterial hypertension: a complex relationship]. G Ital Cardiol (Rome). 2012; 13(6):448-60. DOI: 10.1714/1073.11764. View

19.

Hoeper M, Bogaard H, Condliffe R, Frantz R, Khanna D, Kurzyna M . Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D42-50. DOI: 10.1016/j.jacc.2013.10.032. View

20.

Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N . Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. DOI: 10.1056/NEJMoa1503184. View